BACKGROUND: AT-101 is an oral inhibitor of the antiapoptotic Bcl proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the pro-apoptotic proteins noxa and puma. We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive-stage small cell lung cancer (SCLC). METHODS: Patients with recurrent "sensitive" SCLC (defined as no progression during and no disease recurrence <2 months after completion of first-line platinum-based chemotherapy) were eligible. AT-101 was administered 20 mg orally daily for 21 of 28 days each cycle for up to six cycles. The primary end point was the objective response rate. RESULTS: At the time of planned interim evaluation, none of the 14 evaluable patients enrolled in the first stage had any response to therapy, and the study was closed permanently for further accrual. Three patients (21%) achieved stable disease after two cycles of therapy. Grade 3 toxicities included anorexia, fatigue, and nausea/vomiting. CONCLUSIONS: AT-101 is not active in patients with recurrent chemosensitive SCLC.
BACKGROUND:AT-101 is an oral inhibitor of the antiapoptotic Bcl proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the pro-apoptotic proteins noxa and puma. We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive-stage small cell lung cancer (SCLC). METHODS:Patients with recurrent "sensitive" SCLC (defined as no progression during and no disease recurrence <2 months after completion of first-line platinum-based chemotherapy) were eligible. AT-101 was administered 20 mg orally daily for 21 of 28 days each cycle for up to six cycles. The primary end point was the objective response rate. RESULTS:At the time of planned interim evaluation, none of the 14 evaluable patients enrolled in the first stage had any response to therapy, and the study was closed permanently for further accrual. Three patients (21%) achieved stable disease after two cycles of therapy. Grade 3 toxicities included anorexia, fatigue, and nausea/vomiting. CONCLUSIONS:AT-101 is not active in patients with recurrent chemosensitive SCLC.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: P Bushunow; M M Reidenberg; J Wasenko; J Winfield; B Lorenzo; S Lemke; B Himpler; R Corona; T Coyle Journal: J Neurooncol Date: 1999-05 Impact factor: 4.130
Authors: C Van Poznak; A D Seidman; M M Reidenberg; M M Moasser; N Sklarin; K Van Zee; P Borgen; M Gollub; D Bacotti; T J Yao; R Bloch; M Ligueros; M Sonenberg; L Norton; C Hudis Journal: Breast Cancer Res Treat Date: 2001-04 Impact factor: 4.872
Authors: Ramaswamy Govindan; Nathan Page; Daniel Morgensztern; William Read; Ryan Tierney; Anna Vlahiotis; Edward L Spitznagel; Jay Piccirillo Journal: J Clin Oncol Date: 2006-10-01 Impact factor: 44.544
Authors: Paul K Paik; Charles M Rudin; Andrew Brown; Naiyer A Rizvi; Naoko Takebe; William Travis; Leonard James; Michelle S Ginsberg; Rosalyn Juergens; Susan Markus; Leslie Tyson; Sara Subzwari; Mark G Kris; Lee M Krug Journal: Cancer Chemother Pharmacol Date: 2010-02-18 Impact factor: 3.333
Authors: M R Flack; R G Pyle; N M Mullen; B Lorenzo; Y W Wu; R A Knazek; B C Nisula; M M Reidenberg Journal: J Clin Endocrinol Metab Date: 1993-04 Impact factor: 5.958
Authors: Rathi N Pillai; Joseph Aisner; Suzanne E Dahlberg; John S Rogers; Robert S DiPaola; Seena Aisner; Suresh S Ramalingam; Joan H Schiller Journal: Cancer Chemother Pharmacol Date: 2014-05-24 Impact factor: 3.333
Authors: Kenta Masui; Beatrice Gini; Jill Wykosky; Ciro Zanca; Paul S Mischel; Frank B Furnari; Webster K Cavenee Journal: Carcinogenesis Date: 2013-03-01 Impact factor: 4.944